Target to Treatment (TTT) Consulting Ltd

The #Dose: "The dose makes the poison", as observed by Paracelsus hundreds of years ago, helps us understand that how much of a substance you are exposed to determines whether or not it will cause harm. In drug development we can take this further and consider also that "the dose makes the medicine"! In general, a successful medicine will typically need to have a 'therapeutic window' where the dose is high enough to be effective but low enough to avoid unacceptable adverse effects. During drug development, carefully calculating the estimated dose for use in clinical trials is one of the most crucial steps in ensuring not only trial safety, but also maximising the chances of success. Target to Treatment can help you understand the necessary preclinical work to find a therapeutic window for your asset and how this informs clinical trial design. Get in touch to find out more! #drug #medicine #development #drugDevelopment #clinicalTrials #clinic #safety #efficacy #therapeuticWindow #pharmaceutical #pharmacodynamics #PD #pharmacokinetics #PK #MABEL #theDoseMakesThePoison #theDoseMakesTheMedicine

How can an independent #drugDiscovery and #drugDevelopment #consultancy help you achieve your discovery and development goals? We'd like to tell you! Today our focus is on #Biomarkers, measurable characteristics that indicate biological processes and responses. Biomarkers can be very useful in both #preclinical and #clinical #research, but understanding where they are most useful, which are well validated, and how established they are in your #therapy area can be confusing. Target to Treatment can use our experience to cut through the confusion and help you understand where biomarkers fit into your path to market. Find out more at www.target2treatment.com or contact us to have a chat! #drug #development #discovery #preclinical #clinicalTrials #clinic #biotech #pharma #target #treatment #clinicalPipeline

Have you ever wondered what an independent #DrugDiscovery and #DrugDevelopment #consultancy does? Well, we've been updating our website to tell you! Visit www.target2treatment.com to find out how we can help you achieve your goals. We have experience with a range of clients from #academic to #biotech and #bigPharma. We'll be adding more information on the services offered over time so watch this space! #targetProductProfile #competitorResearch #indicationPrioritisation #translationalBiology #doseEstimation #clinicaltrials #biomarkers #endpoints #CRO #regulators #VC

Idiopathic Pulmonary Fibrosis is a devastating, incurable disease that causes progressive shortness of breath as a result of scarring of the lungs and destruction of alveoli. This film brings to life the plight of patients.

Innovation in the regulatory pathway to treat ultra-rare diseases. These are N = 1diseases and MHRAis leading the way to enable discovery and development of oligo treatments.

This should be very interesting - see you there!

SMR conference: MODULATING RNA WITH OLIGONUCLEOTIDES OR SMALL MOLECULES at Stevenage on Friday 21st June. We'll be there and maybe we'll see you there!! https://lnkd.in/e7RbbuUf

Day 2 of Target to Patient has so far brought interesting thoughts about why drug development has become so expensive, so time-consuming, and what can be done about it. This is an issue we all have an interest in solving to ensure new and better medicines can continue to be developed. Improving the quality of the data and the resultant decision making at each stage of development must play a role. #target2patient #DrugDevelopment

Inspiring to hear from Dr Anna Motyl about the My Name'5 Doddie Foundation and its research strategy to help find new targets and 'catalyse a cure'. Here's hoping their work leads to a new breakthrough in the fight against Motor Neurone Disease (MND). #target2patient

A spirited panel discussion from the Session One speakers! Thought provoking! #target2patient #DrugTargets #TargetSelection #DrugDiscovery #DrugDevelopment